Pharmacological mechanisms of naltrexone and acamprosate in the prevention of relapse in alcohol dependence

American Journal on Addictions

Volumn 12, Issue SUPPL. 1, 2003, Pages s3-s11

  Littleton, John ^a   Zieglgänsberger, Walter ^b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACAMPROSATE; NALTREXONE; NEURAMINIC ACID; OPIATE ANTAGONIST;

ALCOHOLISM; ARTICLE; DRUG ACTIVITY; DRUG MECHANISM; HUMAN; NONHUMAN; RELAPSE;

EID: 0038587675     PISSN: 10550496     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1521-0391.2003.tb00492.x     Document Type: Article

References (54)

1. Littleton JM. The future could be bright! In: Edwards G, Littleton JM, eds. The Pharmacological Treatment for Alcoholism. New York, NY: Croom Helm; 1984:605-614.
2. Monti PM, Robinson DJ, Hutchinson KE. Toward bridging the gap between biological, psychobiological, and psychosocial models of alcohol craving. Addiction. 2000;(suppl 2):S229-236.
3. Koob G. Animal models of craving for ethanol. Addiction. 2000;(suppl 2):S73-81.
4. McBride WJ, Le AD, Noronha A. Central nervous system mechanisms in alcohol relapse. Alcohol Clin Exp Res. 2002;26:280-286.
5. Sillaber I, Rammes G, Zimmermann ST, et al. Enhanced and delayed stress-induced alcohol drinking in mice lacking functional CRH1 receptors. Science. 2002;296:931-933.
6. Schmidhammer H. Opioid receptor anatgonists. Prog Med Chem. 1998;35:83-132.
7. Altshuler HL, Phillips PE, Feinhandler DA. Alteration of ethanol self-administration by naltrexone. Life Sci. 1980;26:679-688.
8. Volpicelli JR, Davis MA, Olgin JE. Naltrexone blocks the post-shock increase of ethanol consumption. Life Sci. 1986;38:841-847.
9. Bienkowski P, Kostowski W, Koros E. Ethanol-reinforced behaviours in the rat: effects of naltrexone. Eur J Pharmacol. 1999;374:321-327.
10. Spanagel R, Zieglgänsberger W. Anti-craving compounds for ethanol: new pharmacological tools to study addictive processes. Trends Pharmacol Sci. 1997;18:54-59.
11. McCaul ME, Wand GS, Eissenberg T, Rohde CA, Cheskin LJ. Nalterxone alters subjective and psychomotor responses to alcohol in heavy drinking subjects. Neuropsychopharmacology. 2000;22:480-492.
12. O'Brien CP, Volpicelli LA, Volpicelli JR. Naltrexone in the treatment of alcoholism: a clinical review. Alcohol 1996;13:35-39.
13. Middaugh LD, Bandy AL. Naltrexone effects on ethanol consumption and response to ethanol conditioned cues in C57B1/6 mice. Psychopharmacology. 2000;151:321-327.
14. Monti PM, Robinson DJ, Hutchinson KE, et al. Nalterxone's effect on cue-elicited craving among alcoholics in treatment. Alcohol Clin Exp Res. 1999;23:1386-1394.
15. Saivin S, Hulot T, Chabac S, Potgeiter A, Durbin P, Houin G. Clinical pharmacokinetics of acamprosate. Clin Pharmacokinet. 1998;35:331-345.
16. Thomas AG, Olkowski JL, Slusher BS. Neuroprotection afforded by NAAG and NAAALAD'ase inhibitors requires glial cells and metabotropic glutamate receptor activation. Eur J Pharmacol. 2001;426:35-38.
17. Zeise ML, Kasparov S, Capogna M, Ziegelgänsberger W. Acamprosate (calcium acetylhomotaurinate) decreases postsynaptic potentials in the rat neocortex: possible involvement of excitatory amino acid receptors. Eur J Pharmacol. 1993;231:47-52.
18. Berton F, Francesconi WG, Madamba S, Zieglgänsberger W, Siggins GR. Acamprosate enhances N-methyl-D-aspartate receptor-mediated neurotransmission but inhibits presynaptic GABAB receptors in nucleus accumbens neurons. Alcohol Clin Exp Res. 1998;22:183-191.
19. Madamba SG, Schweitzer P, Zieglgänsberger W, Siggins GR. Acamprosate (calcium acetylhomotaurinate) enhances the NMDA receptor component of excitatory transmission in rat hippocampal CA1 neurons in vitro. Alcohol Clin Exp Res. 1996;20:651-658.
20. Naassila K, Hammoumi S, Legrand E, Durbin P, Daoust M. Mechanism of action of acamprosate, part I: characterization of spermidine-sensitive acamprosate binding site in rat brain. Alcohol Clin Exp Res. 1998;22:802-809.
21. Al Qatari M, Bouchenafa O, Littleton J. Mechanism of action of acamprosate, part II: ethanol dependence modifies effects of acamprosate on NMDA receptor binding in membranes from rat cerebral cortex. Alcohol Clin Exp Res. 1998;22:810-814.
22. Popp RL, Lovinger D. Interaction of acamprosate with ethanol and spermine on NMDA receptors in primary cultured neurons. Eur J Pharmacol. 2000;394:221-231.
23. Rammes G, Mahal B, Putzke J, et al. The anti-craving compound acamprosate acts as a weak NMDA-receptor antagonist but modulates NMDA-receptor subunit expression similar to memantine and MK-801. Neuropharmacology. 2001;40:749-760.
24. Mayer S, Harris B, Gibson DA, et al. Acamprosate has no effect on NMDA-induced toxicity but reduces toxicity induced by spermidine or by changing the medium in organotypic hippocampal slice cultures from rat. Alcohol Clin Exp Res. 2002;26.
25. Harris BR, Blanchard JA, Holley RC, Gibson DA, Ha LB, Littleton JM. Putative interactions between acamprosate and metabotropic glutamate receptors in ethanol withdrawal. Soc for Neuroscience Abstracts. 2001;27:Prog 980.20.
26. Harris BR, Prendergast M, Gibson DA, Rogers DT, Blanchard JA, Holley RC, Fu M, Hart SR, Pedigo N, Littleton JM. Acamprosate inhibits the binding and neurotoxic effects of t-ACPD suggesting a novel site of action at mGluRs. Alcohol Clin Exp Res. 2002;26:1779-1793.
27. Carpenter KJ, Dickenson AH. Amino acids are still as exciting as ever. Curr Opin Pharmacol. 2001;1:57-61.
28. Morrisett RA, Swartzwelder HS. Attenuation of hippocampal long-term potentiation by ethanol: a patch-clamp analysis of glutamatergic and GABAergic mechanisms. J Neurosci. 1993;13:2264-2272.
29. Lovinger DM, Zieglgänsberger W. Interactions between ethanol and agents that act on the NMDA- type glutamate receptor. Alcohol Clin Exp Res. 1996;20:A187-A191.
30. Mirshahi T, Woodward JJ. Ethanol sensitivity of heteromeric NMDA receptors: effects of subunit assembly, glycine, and NMDAR1 Mg2 +-insensitive mutants. Neuropharmacology. 1995;34:347-355.
31. Hu XJ, Follesa P, Ticku MK. Chronic ethanol treatment produces a selective upregulation of the NMDA receptor subunit gene expression in mammalian cultured cortical neurons. Mol. Brain Res. 1996;36:211-218.
32. Blevins T, Mirshahi T, Woodward JJ. Increased agonist and antagonist sensitivity of N-methyl-D- aspartate stimulated calcium flux in cultured neurons following chronic ethanol exposure. Neurosci Lett. 1995;200:214-218.
33. Hoffman PL, Bhave SV, Kumar KN, et al. The 71 kDa glutamate-binding protein is increased in cerebellar granule cells after chronic ethanol treatment. Mol Brain Res. 1996;39:167-176.
34. Chandler LJ, Sutton G, Norwood D, Sumners C, Crews FT. Chronic ethanol increases N-methyl-D-aspartate-stimulated nitric oxide formation but not receptor density in cultured cortical neurons. Mol Pharmacol. 1997;51:733-740.
35. Breese CR, Freedman R, Leonard SS. Glutamate receptor subtype expression in human postmortem brain tissue from schizophrenics and alcohol abusers. Brain Res. 1995;674:82-90.
36. Freund G, Anderson KJ. Glutamate receptors in the frontal cortex of alcoholics. Alcohol Clin Exp Res. 1996;20:1165-1172.
37. Dahchour A, De Witte P. Ethanol and amino acids in the central nervous system: assessment of the pharmacological actions of acamprosate. Prog Neurobiol. 2000;60:343-362.
38. Spanagel R, Zieglgänsberger W, Hundt W. Acamprosate and alcohol, III: effects on alcohol discrimination in the rat. Eur J Pharmacol. 1996;305:51-56.
39. Grant KA, Woolverton WL. Reinforcing and discriminative stimulus effects of Ca-acetyl homotaurine in animals. Pharmacol Biochem Behav. 1985;32:607-611.
40. Olive MF, Nannini MA, Ou CJ, Koenig HN, Hodge CW. Effects of acute acamprosate and homotaurine on ethanol intake and ethanol stimulated mesolimbic dopamine release. Eur J Pharmacol. 2002;437:55-61.
41. Spanagel R, Sillaber I, Zieglgänsberger W, Corrigall WA, Stewart J, Shaham Y. Acamprosate suppresses the expression of morphine-induced sensitization in rats but does not affect heroin self-administration or relapse induced by heroin or stress. Psychopharmacology. 1998;139:391-401.
42. Le Magnen J, Tran G, Durlach J, Martin C. Dose-dependent suppression of the high alcohol intake of chronically intoxicated rats by calcum acetylhomotaurinate. Alcohol. 1987;4:97-102.
43. Spanagel R, Holter SM, Allingham K, Landgraf R, Zieglgänsberger W. Acamprosate and alcohol, 1: effects on alcohol intake following alcohol deprivation in the rat. Eur J Pharmacol. 1996;305:39-44.
44. Heyser CJ, Schulteis G, Durbin P, Koob GF. Chronic acamprosate eliminates the alcohol deprivation effect while having limited effects on baseline responding for ethanol in rats. Neuropsychopharmacology. 1998;18:125-133.
45. Dahchour A, De Witte P. Acamprosate decreases the hypermotility during repeated ethanol withdrawal. Alcohol. 1999;18:77-81.
46. Sass H, Soyka M, Mann K, Zieglgiinsberger W. Relapse prevention by acamprosate: results from a placebo-controlled study on alcohol dependence. Arch Gen Psychiatry. 1996;53:673-680.
47. Littleton J. Can craving be modeled in animals? The relapse prevention perspective. Addicition. 2000;95(suppl 2):S83-90.
48. Kratzer U, Schmidt WJ. The anti-craving drug acamprosate inhibits the conditioned place aversion induced by naloxone-precipitated morphine withdrawal in rats. Neurosci Lett. 1998;252:53-56.
49. Cole JC, Littleton JM, Little HJ. Acamprosate but not naltrexone inhibits conditioned abstinence behavior associated with repeated ethanol administration in the plus maze. Psychopharmacology. 2000;147:403-411.
50. Dahchour A, DeWitte P, Bolo N, et al. Central effects of acamprosate, part 1: acamprosate blocks the glutamate increase in the nucleus accumbens microdialysate in ethanol withdrawn rats. Psychiatr Res Neuro-imaging 1998;82:107-114.
51. Putzke J, Spanagel R, Tolle TR, Zieglgiinsberger W. The anti-craving drug acamprosate reduces c-fos expression in rats undergoing ethanol withdrawal. Eur J Pharmacol. 1996;317:39-48.
52. Al Qatari M, Khan S, Harris B, Littleton J. Acamprosate is neuroprotective against glutamate-induced excitotoxicity when enhanced by ethanol withdrawal in neocortical cultures of fetal rat brain. Alcohol Clin Exp Res. 2001;25:1276-1283.
53. Mayer S, Harris BR, Gibson DA, Blanchard JA, Prendergast M, Holley RC, Littleton JM. Acamprosate, MK801, and ifenprodil inhibit oneurotoxicity and calcium entry induced by ethanol withdrawal in organotypic slice cultures from neonatal rat hippocampus. Alcohol Clin Exp Res. 2002;26:1468-1478.
54. Schulz B, Fendt M, Gasparini F, Limgenhohl K, Kuhn R, Koch M. The metabotropic glutamate receptor antagonist MPEP blocks fear conditioning in rats. Neuropharmacology. 2001;41:1-7.